Year: 2014
Type: article
Abstract: As diabetes develops, we currently waste the first ∼10 years of the natural history. If we found prediabetes and early diabetes when they first presented and treated them more effectively, we could prevent or delay the progression of hyperglycemia and the development of complications. Evidence for this comes from trials where lifestyle change and/or glucose-lowering medications decreased progression from prediabetes to diabetes. After withdrawal of these interventions, there was no "catch-up"-cumulative development of diabetes in the previously treated groups remained less than in control subjects. Moreover, achieving normal glucose levels even transiently during the trials was associated with a substantial reduction in subsequent development of diabetes. These findings indicate that we can change the natural history through routine screening to find prediabetes and early diabetes, combined with management aimed to keep glucose levels as close to normal as possible, without hypoglycemia. We should also test the hypothesis with a randomized controlled trial.
Source: Diabetes Care
DOI: 10.2337/dc14-0817
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Veterans Affairs, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, Intarcia Therapeutics, Novo Nordisk, National Institutes of Health, Genentech, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: Atlanta Clinical and Translational Science Institute (UL1), UNC Clinical and Translational Science Award, Reach, Outcomes and System Impacts of the VA's National Weight Loss Program, MOVE, Atlanta Clinical and Translational Science Institute (ACTSI) Renewal, Screening for IGT: Glucose Challenge vs Predictive Model, Diabetes Research Center
OpenAlex ID: W1976814223
